JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Crinetics Pharmaceuticals Inc

Suletud

SektorTervishoid

31 2.18

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

30.81

Max

31.39

Põhinäitajad

By Trading Economics

Sissetulek

-16M

-97M

Müük

361K

361K

Kasumimarginaal

-26,807.202

Töötajad

437

EBITDA

-17M

-110M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+133.95% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-262M

2.9B

Eelmine avamishind

28.82

Eelmine sulgemishind

31

Uudiste sentiment

By Acuity

45%

55%

134 / 375 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. juuli 2025, 17:53 UTC

Suurimad hinnamuutused turgudel

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25. juuli 2025, 15:58 UTC

Tulu
Suurimad hinnamuutused turgudel

Aon Shares Rise After 2Q Earnings Beat

25. juuli 2025, 15:08 UTC

Suurimad hinnamuutused turgudel

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25. juuli 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25. juuli 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25. juuli 2025, 20:40 UTC

Tulu

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25. juuli 2025, 20:10 UTC

Tulu

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. juuli 2025, 19:56 UTC

Tulu

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25. juuli 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25. juuli 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25. juuli 2025, 19:01 UTC

Tulu

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. juuli 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25. juuli 2025, 18:35 UTC

Omandamised, ülevõtmised, äriostud

Sale Could Fetch Around $1B, Sources Say -- WSJ

25. juuli 2025, 18:35 UTC

Omandamised, ülevõtmised, äriostud

LVMH in Talks to Sell Marc Jacobs -- WSJ

25. juuli 2025, 18:35 UTC

Omandamised, ülevõtmised, äriostud

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25. juuli 2025, 18:35 UTC

Omandamised, ülevõtmised, äriostud

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25. juuli 2025, 17:38 UTC

Suurimad hinnamuutused turgudel

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25. juuli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25. juuli 2025, 17:13 UTC

Tulu

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25. juuli 2025, 16:46 UTC

Tulu

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25. juuli 2025, 16:45 UTC

Tulu

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25. juuli 2025, 16:27 UTC

Tulu

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. juuli 2025, 16:02 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25. juuli 2025, 15:34 UTC

Tulu

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25. juuli 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25. juuli 2025, 15:05 UTC

Tulu

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25. juuli 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25. juuli 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25. juuli 2025, 14:36 UTC

Market Talk
Tulu

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

133.95% tõus

12 kuu keskmine prognoos

Keskmine 72.5 USD  133.95%

Kõrge 97 USD

Madal 36 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

10

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

30.39 / 33.46Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

134 / 375 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.